| |
MRI halfway through NAC
|
MRI after NAC
|
|---|
|
Percentage of total (N = 75)
|
Tumor response > 50%
|
Diameter reduction > 50%
|
pCR
|
Percentage of total (N = 57)
|
Tumor response > 50%
|
Diameter reduction > 50%
|
pCR
|
|---|
|
Complete radiologic response (type 0)
|
8%
|
90%
|
83%
|
83%
|
20%
|
96%
|
61%
|
41%
|
|
Concentric shrinkage (type 1)
|
40%
|
78%
|
37%
|
26%
|
24%
|
61%
|
44%
|
18%
|
|
Crumbling (type 2)
|
30%
|
65%
|
40%
|
14%
|
23%
|
69%
|
43%
|
8%
|
|
Diffuse enhancement (type 3)
|
2%
|
n.a.
|
n.a.
|
n.a.
|
9%
|
n.a.
|
n.a.
|
n.a.
|
|
Stable disease (type 4)
|
21%
|
53%
|
39%
|
3%
|
24%
|
38%
|
11%
|
4%
|
|
Progressive disease (type 5)
|
1%
|
n.a.
|
n.a.
|
n.a.
|
2%
|
50%
|
0%
|
0%
|
|
Total
|
100%
|
69%
|
41%
|
21%
|
100%
|
65%
|
38%
|
16%
|
- Abbreviations: MRI magnetic resonance imaging, NAC neoadjuvant chemotherapy and immunotherapy, pCR pathological complete response, n.a. not applicable
